|

FDA Approves Expandable Pediatric Pulmonary Valve: Can It Reduce Repeat Surgery?

ByLife Choice Note

Short answer: On October 1, 2026, the U.S. FDA approved the Autus Size-Adjustable Valve for pediatric patients with congenital pulmonary valve disease. It does not biologically grow inside the body. Surgeons implant it first, and clinicians can later enlarge its frame with a balloon catheter as a child grows. The design may reduce repeat open-heart operations, but evidence from 62 patients and very limited post-growth expansion experience does not show that reoperation can be eliminated.

What the FDA approved

The FDA announcement dated October 1, 2026 covers the Autus Size-Adjustable Valve, a surgically implanted pulmonary valve for pediatric patients with congenital pulmonary valve disease who need pulmonary valve replacement.

  • Regulator and date: U.S. FDA, October 1, 2026
  • Patient group: pediatric patients with congenital pulmonary valve disease
  • Device: a surgically implanted valve with synthetic polymer leaflets
  • Regulatory pathway: premarket approval (PMA), used for certain high-risk Class III devices
  • Geographic scope: U.S. marketing approval; it does not establish authorization, availability or insurance coverage in other countries

Does the valve actually grow with a child?

No. “Designed to grow” is shorthand for a frame that can be enlarged after implantation. The valve can be implanted at approximately 13 millimeters in diameter and later expanded with a balloon catheter up to 22 millimeters, a size comparable to an adult pulmonary valve.

The first implantation still requires open-heart surgery. Later expansion is performed through a less invasive catheter procedure. Clinicians would base the timing on imaging, blood-flow measurements, regurgitation, pressure gradients, anatomy and the patient’s overall condition—not age or height alone.

Why this design is different

A fixed-size replacement valve can become relatively too small as a child’s heart and body grow. Traditional tissue valves may also calcify or deteriorate faster in younger patients, creating the possibility of additional operations.

The Autus valve addresses both problems differently: its frame can be enlarged later, and its leaflets are made from polymer rather than animal-derived tissue. The FDA describes it as the first approved heart valve using polymeric leaflets for any indication. That first-in-class status does not yet prove superior long-term durability.

What the 62-patient approval study found

The FDA based approval on a clinical study enrolling 62 pediatric patients at 12 U.S. sites. At six months, the first 60 patients showed acceptable right-sided heart blood-flow performance and no more than mild pulmonary valve leakage.

  • All 62 patients had a successful implantation procedure.
  • FDA reported no deaths, strokes, blood clots requiring additional treatment or other clot-related complications.
  • Three patients had a valve-frame fracture and two had reduced movement of one leaflet; none had symptoms from these findings at the time reported.
  • Two patients whose valves began to become too small underwent successful catheter expansion without another open operation.

An earlier published U.S. early-feasibility study followed 11 patients at three centers for one year. It reported intact valve function, no deaths and no device-related adverse events. But it was a small, prospective, single-arm study, so it could not establish comparative long-term benefit.

Can it prevent repeat open-heart surgery?

That is the goal, not yet a guaranteed outcome. The FDA says the valve may reduce repeat operations. Only two patients in the approval report had undergone post-growth expansion, so the evidence cannot yet show how often expansion will avoid surgery, how many expansions remain safe over childhood, or how the device compares with established surgical valves over many years.

The frame fractures and reduced leaflet movement also make long-term surveillance important even though they had not caused symptoms in the reported follow-up. Ongoing studies are collecting information about durability, function after expansion and the eventual need for another intervention.

What families should understand about the approval

  • This is not a valve for every congenital heart defect. It is intended for selected pediatric patients who need pulmonary valve replacement.
  • The initial procedure is surgery; later size adjustment is catheter-based. It is not a “no-surgery” valve.
  • FDA approval applies to the United States and does not automatically determine access or coverage elsewhere.
  • Valve choice and timing depend on anatomy, prior repairs, heart function and the experience of a congenital heart team.

Key limitations

  • The FDA’s headline performance results use six-month follow-up, which is too short to establish childhood-to-adult durability.
  • The approval study included 62 patients, and post-growth expansion experience remains very limited.
  • The published early-feasibility study included 11 patients and had no randomized comparison group.
  • U.S. study and regulatory findings do not establish approval, availability, clinician experience or reimbursement in another country.
  • This explainer does not recommend an operation, valve or treatment schedule for any individual patient.

Primary sources checked

Prepared by: Life Choice Note, an independent personal health-information explainer
Reviewed: October 5, 2026
Purpose: General explanation of regulatory evidence and original research. This article does not provide individual diagnosis, surgical advice or treatment instructions.

Related guides